Tumor burden at the time of UCART19 infusion did not significantly correlate with UCART19 cellular kinetics in contrast to previous autologous CAR-T cell studies that have shown a positive correlation between CAR-T cell expansion and overall tumor burden or CD19+ cells in BM (16, 26, 29, 33, 45). The gene discussed is CD19; the disease is neoplasm.